Lilly partners with Haya for lncRNA obesity target deal worth $1bn

Sep 5, 2024 · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

CouponFollow Extension

$1
OFF

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 5, 2024 · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

pharmaceutical-technology.com

$1
OFF

Lilly, Haya Ink $1B Biobuck Obesity Pact To Search Dark Genome

4 weeks from now

Sep 4, 2024 · Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find …

fiercebiotech.com

$1
OFF

Lilly Lays Down $1B To Be ‘first In Biology’ With Obesity Gene ...

4 weeks from now

Sep 9, 2024 · Last week, Lilly struck a deal with Haya Therapeutics, a Switzerland and San Diego-based biotech in the early phases of lncRNA development targeting chronic diseases. …

pharmavoice.com

$1
OFF

Lilly To Hunt Non-coding DNA For Obesity Drugs In $1bn Deal

4 weeks from now

6 days ago · Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA. The biotech focuses on …

pharmaphorum.com

$1
OFF

Lilly, Haya Ink Potential $1B Drug Discovery Deal To Target Obesity …

4 weeks from now

Sep 4, 2024 · Eli Lilly is diving further into the obesity space with a potential billion-dollar deal with Haya Therapeutics. The companies announced a collaboration Wednesday to utilize the Swiss …

biospace.com

$1
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration. Pharma giant plans to apply Swiss biotech’s RNA-guided regulatory genome platform to support preclinical drug discovery …

genengnews.com

$1
OFF

Haya, Lilly Target Metabolic Disorders With $1B LncRNA Pact

4 weeks from now

Sep 4, 2024 · The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech pioneers and big pharma in the past week. Haya …

bioworld.com

$1
OFF

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 7, 2024 · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

borderless.net

$1
OFF

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 5, 2024 · Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.

pharmaceutical-technology.com

FAQs about Lilly partners with Haya for lncRNA obesity target deal worth $1bn Coupon?

Will Lilly pay Haya a $1 billion lncRNA investment?

Lilly has agreed to pay HAYA an undisclosed upfront payment, including an equity investment, as well as up to $1 billion in payments tied to achieving preclinical, clinical, and commercial milestones, plus royalties on product sales. Lilly is the second big-name biopharma to invest in an lncRNA collaboration in as many weeks. ...

Could Haya get $1bn from Eli Lilly?

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal. Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. ...

What is Haya's lncRNA collaboration?

This collaboration will utilize HAYA’s full-stack regulatory genome platform to identify, characterize and validate multiple novel lncRNA targets for the potential development of new treatments for obesity and related metabolic disorders. ...

Does Eli Lilly have a dark genome?

Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets. ...

Will Lilly invest in lncRNA?

Lilly is the second big-name biopharma to invest in an lncRNA collaboration in as many weeks. Bayer joined NextRNA Therapeutics to announce an up-to-$547 million partnership aimed at developing small molecule therapeutics targeting lncRNAs in oncology. ...

Could Haya's lncRNA discovery lead to the development of Genetic Medicine?

“By identifying disease-driving cell states and novel lncRNA therapeutic targets, Haya’s proprietary regulatory genome discovery platform may pave the way for the development of genetic medicine therapies that modify disease cell states, augmenting the efficacy of current obesity targeting therapies.” ...